NCT06971198View on ClinicalTrials.gov

Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

March 28, 2025

Study Completion Date

May 6, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

HSK39004

0.75\~4mg

DRUG

Placebo

0.75\~4mg

Trial Locations (1)

Unknown

Shandong Provincial Qianfoshan Hospital, Jinan

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY